Product
BBV87
1 clinical trial
1 indication
Indication
ChikungunyaClinical trial
A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety And Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya Vaccine In Healthy Subjects Aged 12 to 65 Years in Latin America and Asia.Status: Active (not recruiting), Estimated PCD: 2022-07-19